1. A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Issue 10 (13th March 2020) Authors: Puduvalli, Vinay K; Wu, Jing; Yuan, Ying; Armstrong, Terri S; Vera, Elizabeth; Wu, Jimin; Xu, Jihong; Giglio, Pierre; Colman, Howard; Walbert, Tobias; Raizer, Jeffrey; Groves, Morris D; Tran, David; Iwamoto, Fabio; Avgeropoulos, Nicholas; Paleologos, Nina; Fink, Karen; Peereboom, David; Chamberla... Journal: Neuro-oncology Issue: Volume 22:Issue 10(2020) Page Start: 1505 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ACTR-03. A FEASIBILITY TRIAL OF THE MODIFIED ATKINS DIET AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA. (5th November 2018) Authors: Rogers, Lisa; Rolfe, Sarah; Devine, Karen; Peereboom, David; Palcsik, Michelle; Hamza, Mohamed; Riehl, Ann; Marsey, Marge; Berger, Nathan A; Gibbons, Joseph; Barnholtz-Sloan, Jill; Sloan, Andrew; Tatsuoka, Curt Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. ACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. (5th November 2018) Authors: Peereboom, David; Lathia, Justin; Alban, Tyler; Mohammadi, Alireza; Ahluwalia, Manmeet; Brewer, Cathy; Vogelbaum, Michael Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS. (5th November 2018) Authors: Puduvalli, Vinay; Wu, Jing; Yuan, Ying; Armstrong, Terri; Wu, Jimin; Giglio, Pierre; Xu, Jihong; Colman, Howard; Walbert, Tobias; Raizer, Jeffrey; Groves, Morris; Iwamoto, Fabio; Tran, David; Avgeropoulos, Nicholas; Paleologos, Nina; Fink, Karen; Peereboom, David; Chamberlain, Marc; Merrell, Ryan... Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM. (5th November 2018) Authors: Alexander, Brian; Supko, Jeffrey; Agar, Nathalie; Ahluwalia, Manmeet; Desai, Arati; Dietrich, Jorg; Kaley, Thomas; Peereboom, David; Takebe, Naoko; Desideri, Serena; Fisher, Joy; Sims, Megan; Ye, Xiaobu; Ligon, Keith; Nabors, L Burt; Grossman, Stuart; Wen, Patrick Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. ACTR-26. SAFETY AND EFFICACY OF BEVACIZUMAB PLUS TTFIELDS IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM): DATA FROM A PHASE II CLINICAL TRIAL. (11th November 2019) Authors: Fallah, Jaleh; Chaudhary, Rekha; Rogers, Lisa; (Auston) Wei, Wei; Brewer, Cathy; Peereboom, David; Ahluwalia, Manmeet Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. ACTR-43. GENOMIC ANALYSIS OF RESPONDERS OF PHASE II TRIAL OF TEMOZOLOMIDE AND TRC-102 (BASE EXCISION REPAIR INHIBITOR) IN BEVACIZUMAB-NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE. (11th November 2019) Authors: Ahluwalia, Manmeet; Dhruv, Harshil; Fallah, Jaleh; Berens, Michael; Drappatz, Jan; Ye, Xiaobu; Lesser, Glenn; Cloughesy, Timothy; Walbert, Tobias; Holdhoff, Matthias; Peereboom, David; Nabors, Louis; Wen, Patrick; Grossman, Stuart; Rogers, Lisa Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. ACTR-58. BASELINE REQUIREMENTS FOR NOVEL AGENTS BEING CONSIDERED FOR BRAIN CANCER EFFICACY TRIALS: REPORT OF AN ABTC WORKSHOP. (11th November 2019) Authors: Grossman, Stuart; Romo, Carlos; Rudek-Renaut, Michelle; Supko, Jeffrey; Fisher, Joy; Nabors, Burt; Wen, Patrick; Peereboom, David; Ellingson, Benjamin; Ye, Xiaobu Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. ATIM-40. CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS PREDICT FAVORABLE RESPONSE TO IMMUNE CHECKPOINT THERAPY IN A RANDOMIZED TRIAL OF NIVOLUMAB AND BEVACIZUMAB IN RECURRENT GBM. (11th November 2019) Authors: Ahluwalia, Manmeet; Grabowski, Matthew; Alban, Tyler; Otvos, Balint; Bayik, Defne; Saeed Bamashmos, Anas; Rayman, Patricia; Diaz-Montero, Marcela; Reardon, David; Wen, Patrick; Peereboom, David; Lathia, Justin Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. ATIM-41. PHASE II TRIAL OF A SURVIVIN VACCINE (SurVaxM) For Newly Diagnosed Glioblastoma. (5th November 2018) Authors: Ahluwalia, Manmeet; Reardon, David; Abad, Ajay; Curry, William; Wong, Eric; Peereboom, David; Belal, Ahmed; Qiu, Jingxin; Mogensen, Kathleen; Schilero, Cathy; Casucci, Danielle; Mechtler, Laszlo; Uhlmann, Erik; Ciesielski, Michael; Fenstermaker, Robert Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗